Your SlideShare is downloading. ×
  • Like
Final M&A 2003
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Final M&A 2003

  • 1,140 views
Published

7ppts on M&A wth example of ranbaxy

7ppts on M&A wth example of ranbaxy

Published in Business , Economy & Finance
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
1,140
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
81
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1.
  • 2. Incentives for Mergers and Acquisitions by Indian companies
    • Build critical mass in terms of marketing, manufacturing and research infrastructure
    • 3. Establish front end presence
    • 4. Diversification into new areas
    • 5. Enhance product, technology and intellectual property portfolio
    • 6. Catapulting market share
  • 7.
  • 8. About Ranbaxy
    • Incorporated in 1961
    • 9. Came with IPO in 1973
    • 10. Global footprint in 49 countries
    • 11. World-class manufacturing facilities in 11 countries
    • 12. Serves customers in over 125 countries
  • 13.
  • 14.
  • 15.
    • Acquired 34.8% promoter stake of Ranbaxy at a price of Rs.737 per share
    • 16. Transaction value = US$ 4.6 billion (Rs.19780 crores.)
    (Currency Exchange Rate 1US$ = Rs.43)
    • Financed through a mix of bank debt facilities and existing cash resources of Daiichi Sankyo
    About the deal
  • 17. About the deal
    • Total no. of shares acquired : 220.6 million
    • 18. Through open offer : 92.5 million
    • 19. From the promoter : 81.9 million
    • 20. Through the preferential issue
    of equity shares and warrants 46.2 million
  • 21. Benefits to Daiichi Sankyo Ltd.
    • Ranbaxy’s:
    low-cost manufacturing infrastructure and
    supply chain strengths
    • Elevate the Daiichi Sankyo’s position from 22 to 15 by market capitalization in the global pharmaceutical market.
  • Benefits to Ranbaxy Ltd.
    • Ranbaxy gains access to Daiichi Sankyo’s research and development expertise to advance its branded drugs business.
    • 22. The deal frees up its debt and imparts more flexibility into its growth plans.
  • SYNERGY
  • 23. Long-term value for all stakeholders
    • A complementary business combination
    • 24. An expanded global reach
    • 25. Strong growth potential
    • 26. Cost competitiveness
  • 27.
  • 28. REFERENCES
    Research report by Daiichi Sankyo Ltd.
    Economic Times dated 12th June, 2008.
    The Financial Express dated 21st Oct.,2008.